Risk stratification of acute myeloid leukemia

Abstract

Patients with acute myeloid leukemia (AML) present a great heterogeneity in clinical presentation and prognosis, and adequate risk stratification before treatment is particularly important in selecting a rational treatment. In addition, a standardized dynamic minimal residual disease (MRD) analysis during treatment will improve early prediction of leukemia relapse and timely intervention. In addition to routine prognostic stratification, newly discovered molecular markers in recent years provide new effective markers for risk stratification and MRD monitoring of AML. Key words: Leukemia, myeloid, acute; Prognosis; Risk stratification